Evidence map›Paper›PMID 38444884›Full record

ArticleThe Lancet regional health. Southeast Asia2024

Treatment regimens and survival among patients with head and neck squamous cell carcinoma from Mizo tribal population in northeast India - a single centre, retrospective cohort study.

Zothan Zami, Lallianmawii Pachuau, Zothankima Bawihtlung, Lalfakzuala Khenglawt, Lal Hlupuii, Cindy Lalthanpuii, Vanlal Hruaii, Hauhnar Lalhruaitluanga, Nachimuthu Senthil Kumar

Open access · diamondAbstract read
In one paragraph

Article in The Lancet regional health. Southeast Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zothan ZamiDepartment of Biotechnology, Mizoram University, Tanhril, 796004, Aizawl, Mizoram, India.
Lallianmawii PachuauDepartment of Biotechnology, Mizoram University, Tanhril, 796004, Aizawl, Mizoram, India.
Zothankima BawihtlungMizoram State Cancer Institute, Zemabawk, 796017, Aizawl, Mizoram, India.
Lalfakzuala KhenglawtMizoram State Cancer Institute, Zemabawk, 796017, Aizawl, Mizoram, India.
Lal HlupuiiMizoram State Cancer Institute, Zemabawk, 796017, Aizawl, Mizoram, India.
Cindy LalthanpuiiMizoram State Cancer Institute, Zemabawk, 796017, Aizawl, Mizoram, India.
Vanlal HruaiiMizoram State Cancer Institute, Zemabawk, 796017, Aizawl, Mizoram, India.
Hauhnar LalhruaitluangaDepartment of Biotechnology, Mizoram University, Tanhril, 796004, Aizawl, Mizoram, India.
Nachimuthu Senthil KumarDepartment of Biotechnology, Mizoram University, Tanhril, 796004, Aizawl, Mizoram, India.
Cancer Institute (WIA) · INMizoram University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with early-stage head and neck squamous cell carcinoma (HNSCC) are treated using a single-modality approach that involves either surgery (S) or radiotherapy (RT). Conversely, those with advanced-stage disease are treated using a multi-modality approach incorporating a combination of chemotherapy (CT), RT and S. In addition to behavioural factors, such as alcohol and tobacco use, clinical parameters, such as leukocyte and neutrophil counts and T and N classification, have been linked to the survival of patients with head and neck cancer. This retrospective study was designed to provide insights into the types of treatment (induction chemotherapy [IC], concurrent chemoradiotherapy [CCRT], S and RT) administered to patients with HNSCC in Mizoram, analyse their 2-year outcome, and identify potential factors that may affect the response to treatment. Methods: A retrospective cohort study was conducted using patients diagnosed with HNSCC between 2017 and 2020 in Mizoram, northeast India. Data on clinical and demographic factors and treatments provided were collected from medical records from the Mizoram State Cancer Institute, Mizoram. Overall survival (OS) and progression free survival (PFS) were determined for each factor using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was used to identify the factors that affected OS and PFS. Multicollinearity test was performed between the predictors using a variance inflation factor cut-off point of 2. Findings: A retrospective study was performed on 210 patients with HNSCC who were followed up for a period of 2 years. The findings revealed that hypopharynx was the most affected site, followed by the nasopharynx, oral cavity, oropharynx, and larynx. Regarding treatment regimens, 85/210 (40.5%) of the patients received IC along with CCRT or RT in a sequential manner. Moreover, 86/210 (41.0%) underwent CCRT alone, 22/210 (10.5%) received RT alone and 17/210 (8.1%) underwent surgery followed by adjuvant CCRT or RT. Two-year OS and PFS estimated using the Kaplan-Meier analysis were 78.1% (95% CI = 72.4%-84.2%) and 57.4% (95% CI = 50.8%-64.8%), respectively. Log-rank test showed that leucocytosis (p = 0.015) and neutrophilia (p = 0.014) exerted effects on OS, whereas nodal involvement (p = 0.005), neutrophilia (p = 0.043) and IC (p = 0.010) exerted effects on PFS. Multivariate analysis indicated that leucocytosis (p = 0.010 [OS], 0.025 [PFS]), neutrophilia (p = 0.029, 0.033), cancer site (laryngeal) (p = 0.009, 0.028) and nodal involvement (N2) (p = 0.020, 0.001) were predictors of poor OS and PFS. Interpretation: OS was better than PFS in HNSCC patients from Mizo population. Multi-modality approach offered survival advantages over single-modality approach. Leucocytosis, neutrophilia, nodal involvement, and cancer sites were associated with poor OS and PFS. More comprehensive research with a larger sample size is needed to confirm the findings from this study. Funding: There is no funding for this study.

Indexed as

Concurrent chemoradiotherapyHead and neck cancerInduction chemotherapyOverall survivalProgression free survival

Identifiers

PMID38444884
PMCPMC10914477
OpenAlexW4392438377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.